Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer
Sign Up to like & getrecommendations! Published in 2020 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-00965-8
Abstract: Background Previous studies on neoadjuvant therapy for BRCA1-driven ovarian cancer (OC) demonstrated higher efficacy of mitomycin C plus cisplatin combination as compared to standard drug schemes. These data call for evaluation of the utility of… read more here.
Keywords: mitomycin plus; treatment; recurrent brca1; ovarian cancer ... See more keywords